Brief: Compass Therapeutics Inc. Tovecimig Plus Paclitaxel Improves Median Pfs To 4.7 Months Versus 2.6 Months
27/04/2026 13:32
April 27 (Reuters) - Compass Therapeutics Inc. CMPX.O: COMPASS THERAPEUTICS INC. - TOVECIMIG PLUS PACLITAXEL IMPROVES MEDIAN PFS TO 4.7 MONTHS VERSUS 2.6 MONTHS TOVECIMIG DEMONSTRATES STATISTICALLY SIGNIFICANT BENEFIT IN COMPANION-002 RANDOMIZED PHASE 2/3 STUDY IN PATIENTS WITH BILIARY TRACT CANCER COMPASS THERAPEUTICS INC. - CROSSOVER PATIENTS SHOW MEDIAN OS OF 12.8 MONTHS VERSUS 6.1 MONTHS FOR NON-CROSSOVER COMPASS THERAPEUTICS INC.: MET KEY SECONDARY ENDPOINT OF PFS AND SHOWED ADDITIONAL COMPELLING RESULTS IN RANDOMIZED COMPANION-002 STUDY Source text: ID:nGNX3GGsh5 Further company coverage: CMPX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Compass Therapeutics
See all newsBrief: Compass Announces Inducement Grants Under Nasdaq Listing Rule
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
U.S. STOCKS ON THE MOVE-Vicor, Thor Industries, Lennar
Brief: Compass Therapeutics Provides Regulatory Update On Tovecimig In Biliary Tract Cancer Following FDA Feedback